Safety issues with glucagonlike peptide1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
The GLP1R/GIPR dual agonist NNC 00902746 (Novo Nordisk) significantly improved hemoglobin A1c (A1c) in T2DM (a reduction of 0.96% vs placebo) over a 12-week period, accompanied by a reduction in body weight
After administering, adequate protein needs to be ingested for IGF-1 to be effective in building new muscle
You should get B12 shots weekly to monthly for maintenance and IV infusions monthly to quarterly for broader wellness support, though frequency depends on deficiency severity, health goals, and your providers recommendation
Compounded GLP-1 medications are not FDA-approved